Healthcare Stocks To Watch: Gilead Sciences Inc. (GILD), Zosano Pharma Corporation (ZSAN)

Andrew Cummings
February 16, 2017

Its previous fifty two week high was $8.49 and moved down -68.05% over the same time frame, now having a market cap around $432.8 million. Trading volume may be a very important factor for any investor. The most recent downgrade was reported by Ladenburg Thalmann on Aug 11, 2016, with a rating change from Buy to Neutral.

Analysts mean target price for Zosano Pharma Corporation (NASDAQ:ZSAN) is $2.00 while their mean recommendation is 2.00 (1=Buy, 5=sell).

Zosano Pharma Corporation is a biopharmaceutical company.


The firm is trading with SMA20 of 132.27 Percent, SMA50 of 174.8 Percent and SMA200 of 151.89 percent. Zosano Pharma Corporation P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0. The company's stock has a Return on Assets (ROA) of -82.8 percent, a Return on Equity (ROE) of -170.3 percent and Return on Investment (ROI) of -64.1 percent. The study demonstrated a statistically significant 2-hour pain freedom response rate with a low placebo rate for the primary endpoint. Number of analysts are covering this stock and now stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 1 analyst given HOLD rating to the stock and 0 given UNDERPERFORM rating. Sales during the quarter are predicted to arrive at $0. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.

Analysts are speculating a 14.04% move, based on the high target price ($3.25) for the shares that is set to reach in the next 12 months. The median estimate represents a -7.41% decrease from the last price of 1.62. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Following Earnings result, share price were UP 4 times out of last 6 Qtrs. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold.


According to Zacks Investment Research, Novavax, Inc. has a Consensus Recommendation of 2.67. The company has the Market capitalization of $152.58 Million. The Gaithersburg Maryland 20878 based company is now trading 39.66% above its 52 week low of $1.16 and -80.92% below its 52 week high of $8.49. The consensus recommendation 30 days ago for this company stood at 1.67. The company has volume of 31.31 Million shares. There were about 267.16M shares outstanding which made its market cap $432.8M. Lombard Odier Asset Management USA Corp now owns 795,722 shares of the company's stock valued at $615,000 after buying an additional 318,450 shares during the last quarter. The difference between the actual and Estimated EPS is $0.02. The stock is showing its Operating Margin of 0 percent.

Novavax, Inc. (NASDAQ:NVAX) last exchanged hands at a price $1.62/share, registering a gain of 14.08%. The firm now has a "buy" rating on the stock.

The Company now has ROA (Return on Assets) of -61.5 percent, Return on Equity (ROE) of -189.1 Percent and Return on Investment (ROI) of -53.6% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER